Miranda GLM, Hernández RG, Quirós PF

Language: Spanish
References: 16
Page: 12-15
PDF size: 44.02 Kb.

ABSTRACT

Patients with differentiated thyroid cancer after initial treatment require a pursuit for life. In the pursuit of patient with differentiated thyroid cancer is suitable the realization of either rake with iodine 131 or with technetium 99–sestamibi. The objective of the present study is to know which radiopharmaceutical has bigger certainty in the detection of tissue remainder and/or metastatic. Twenty-six patients were selected with differentiated thyroid cancer, to the same patient they were made rake, with technetium 99-sestamibi and with Iodine 131; the results of the two studies and the statystical analysis were compared it was carried out by means of the test of Chi square. Nine patients were positive for iodine 131 (34%) and 5 (19%) positive for technetium 99-sestamibi, obtaining a significant p (p ‹ 0.05). The sensibility reported for the iodine 131 was of 70%, with a specificity of 19%; the sensibility obtained for the technetium 99-sestamibi is approximately of 19%. In our study to be better the iodine 131 that the technetium 99-sestamibi in the detection of fabric residual and/or metastatic. The biggest advantage in the technetium 99-sestamibi is its application without necessity of suspending the treatment with hormonal, but on the other hand the biggest disadvantage is its low sensibility in differentiated carcinoma.

REFERENCES

1. Robbins J, Merino MJ, Boice JD. Thyroid cancer: A lethal endocrine neoplasm. Ann Intern Med 1991; 115: 133-47.

2. Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levy EG, Braverman LE, Clark OH, McDougall IR, Ain KV, Dorfman SG. Treatment Guidelines for patients with thryroid nodules and well-differentiated thyroid cancer. Arch Intern Med 1996; 156: 2165-72.

3. Utiger RD. Follow-up of patients with thyroid carcinoma. N Engl J Med 1997; 337: 928-930.

4. Steven IS. Toward a stander clinicopathologic station approach for differentiated thyroid carcinoma. Semin Surg Oncol 1999; 16: 12-15.

5. Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997; 7: 265-71.

6. Maxon HR. Detection of residual and recurrent thyroid cancer by radionuclide imaging. Thyroid 1999; 9: 443-46.

7. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, Degroot LJ. Serum thryroglobulin in the follow-up of patients treated with differentiated thyroid cancer. J Clin Endocrinol Metab 1994; 79: 98-105.

8. Ladenson PW, Braverman LE, Mazzaferri EL, Davis FB, Cooper DS, Garber JR, Wondisford FE, Davies TF, Degroot LJ, Daniels GH, Ross DS, Weintraub BD. Comparison of administration of recombinant human thyrotropin with and withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997; 337: 888-95.

9. Maxon HR, Smith HS. Radiodine-131 in the diagnosis treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990; 19: 685-718.

10. Balon HR, Bennett-Fink D, Stoffer SS. Technetium-99 m-sestamibi uptake by recurrent Hurtle cell carcinoma of the thyroid. J Nucl Med 1992; 33: 1393-95.

11. Sanders LE, Siverman M. Follicular and Hurtle cell carcinoma: Predicting outcome and directin therapy. Surgery 1998; 124: 967-74.

12. Steven IS. Adjuvant therapy and long-term management of differentiated thyroid carcinoma. Semin Surg Oncol 1999; 16: 30-3.

13. Spencer CA, Lopresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 1999; 9: 435-41.

14. Grunwald F, Menzel C, Bender H, Palmedo H, Willkomm P, Ruhlmann J, Franckson T, Biersack HJ. Comparison of 18 FDG-PET with 131 iodine and 99 m Tc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997; 7: 327-35.

15. Ladenson PW. Strategies for thyrotropin use to monitor patients with treated thyroid carcinoma. Thyroid 1999; 9: 429-33.

16. Dadparvar S, Chevres A, Tulchilsky M, Badrinath LK, Khan AS, Slizofski WJ. Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thalium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation. Eur J Nucl Med 1995; 22: 1330-38.